769 related articles for article (PubMed ID: 33334622)
1. Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease.
Makri E; Goulas A; Polyzos SA
Arch Med Res; 2021 Jan; 52(1):25-37. PubMed ID: 33334622
[TBL] [Abstract][Full Text] [Related]
2. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
Streba LA; Vere CC; Rogoveanu I; Streba CT
World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
[TBL] [Abstract][Full Text] [Related]
3. Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease.
Satapathy SK; Sanyal AJ
Semin Liver Dis; 2015 Aug; 35(3):221-35. PubMed ID: 26378640
[TBL] [Abstract][Full Text] [Related]
4. [Non-alcoholic fatty liver disease; a full-bodied epidemic].
Tushuizen ME; Holleboom AG; Koot BGP; Blokzijl H; van Mil SWC; Koek GH
Ned Tijdschr Geneeskd; 2020 Feb; 164():. PubMed ID: 32267638
[TBL] [Abstract][Full Text] [Related]
5. Nonalcoholic Fatty Liver Disease.
Isaacs S
Endocrinol Metab Clin North Am; 2023 Mar; 52(1):149-164. PubMed ID: 36754491
[TBL] [Abstract][Full Text] [Related]
6. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.
Zhou JH; Cai JJ; She ZG; Li HL
World J Gastroenterol; 2019 Mar; 25(11):1307-1326. PubMed ID: 30918425
[TBL] [Abstract][Full Text] [Related]
7. Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments.
Roeb E; Geier A
Z Gastroenterol; 2019 Apr; 57(4):508-517. PubMed ID: 30965381
[TBL] [Abstract][Full Text] [Related]
8. Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis.
Marengo A; Rosso C; Bugianesi E
Annu Rev Med; 2016; 67():103-17. PubMed ID: 26473416
[TBL] [Abstract][Full Text] [Related]
9. Non-invasive diagnosis of nonalcoholic fatty liver disease in patients with type 2 diabetes.
Alhinai A; Patel K; Fonseca VA; Sebastiani G
J Diabetes Complications; 2021 Sep; 35(9):107978. PubMed ID: 34183247
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
Perumpail RB; Wong RJ; Ahmed A; Harrison SA
Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
[TBL] [Abstract][Full Text] [Related]
11. [Advances in diagnosis and treatment of nonalcoholic fatty liver disease].
Zhu C; Zhou D; Fan J
Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):81-4. PubMed ID: 26983471
[TBL] [Abstract][Full Text] [Related]
12. AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review.
Long MT; Noureddin M; Lim JK
Gastroenterology; 2022 Sep; 163(3):764-774.e1. PubMed ID: 35842345
[TBL] [Abstract][Full Text] [Related]
13. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation.
Younossi ZM
Liver Transpl; 2018 Feb; 24(2):166-170. PubMed ID: 29272073
[TBL] [Abstract][Full Text] [Related]
14. Clinical indicators for progression of nonalcoholic steatohepatitis to cirrhosis.
Seen TK; Sayed M; Bilal M; Reyes JV; Bhandari P; Lourdusamy V; Al-Khazraji A; Syed U; Sattar Y; Bansal R
World J Gastroenterol; 2021 Jun; 27(23):3238-3248. PubMed ID: 34163108
[TBL] [Abstract][Full Text] [Related]
15. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts.
Alexander M; Loomis AK; van der Lei J; Duarte-Salles T; Prieto-Alhambra D; Ansell D; Pasqua A; Lapi F; Rijnbeek P; Mosseveld M; Waterworth DM; Kendrick S; Sattar N; Alazawi W
BMC Med; 2019 May; 17(1):95. PubMed ID: 31104631
[TBL] [Abstract][Full Text] [Related]
16. Nonalcoholic fatty liver disease and hepatocellular carcinoma:Insights in epidemiology, pathogenesis, imaging, prevention and therapy.
Polyzos SA; Chrysavgis L; Vachliotis ID; Chartampilas E; Cholongitas E
Semin Cancer Biol; 2023 Aug; 93():20-35. PubMed ID: 37149203
[TBL] [Abstract][Full Text] [Related]
17. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.
Massoud O; Charlton M
Clin Liver Dis; 2018 Feb; 22(1):201-211. PubMed ID: 29128057
[TBL] [Abstract][Full Text] [Related]
18. The Effects of Hepatic Steatosis on the Natural History of HBV Infection.
Suliman I; Abdelgelil N; Kassamali F; Hassanein TI
Clin Liver Dis; 2019 Aug; 23(3):433-450. PubMed ID: 31266618
[TBL] [Abstract][Full Text] [Related]
19. New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis.
Pydyn N; Miękus K; Jura J; Kotlinowski J
Pharmacol Rep; 2020 Feb; 72(1):1-12. PubMed ID: 32016853
[TBL] [Abstract][Full Text] [Related]
20. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies.
Stefan N; Häring HU; Cusi K
Lancet Diabetes Endocrinol; 2019 Apr; 7(4):313-324. PubMed ID: 30174213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]